Abcam board of directors

Michael Redmond
MA (Cantab), 67
Chairman

Mike Redmond, who joined Abcam in February 2009, has substantial international experience in the pharmaceutical industry gained in both executive and non-executive capacities at businesses ranging from multinational organisations to start-up companies. He is currently chairman of Dechra Pharmaceuticals plc and his recent chairmanships include Synexus Clinical Research plc, Arakis Limited and Microscience Limited. His executive career began at Glaxo Group plc in 1967 and he has held senior executive positions in marketing and management at companies including Schering Plough Corporation and Fisons plc.

Jonathan Milner, PhD, 46
CEO

Jonathan Milner is an experienced entrepreneur and business leader with a background in genetic research. He gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University. From 1992 to 1995 he was a postdoctoral researcher at Bath University, following which he worked at the University of Cambridge in the laboratory of Professor Tony Kouzarides studying cancer, specifically the BRCA2 gene in hereditary breast cancer. Whilst in research he identified the market opportunity for supplying high quality antibodies to support protein interaction studies. In 1998, Jonathan founded the internet-based business Abcam, with David Cleevely and Professor Tony Kouzarides, to supply the rapidly growing market for antibodies and related products. Jonathan is an active supporter of the Cambridge business community. He is chairman of Cambridge Temperature Concepts (CTC), a medical device company with a platform technology in wireless temperature sensing. CTC’s first product is an accurate system for ovulation monitoring. Jonathan is also a non-executive director of Horizon Discovery, a personalised genomics company.

Jeff Iliffe, BSc, ACA, 50
CFO / Company Secretary

Jeff Iliffe is a qualified accountant who was appointed as Abcam's Chief Financial Officer in November 2007, having previously worked for the Company as a financial consultant. He has extensive relevant experience of the City, industry and internet-based business. Jeff was a corporate financier in life sciences at Panmure Gordon & Co. between 1989 and 1996. He then moved into industry, holding a number of financial positions at companies including the environmental consultancy Enviros Group Limited and the biotechnology company Plethora Solutions plc. Prior to joining Abcam, he was chief financial officer at the eCommerce company St Minver Ltd.

Jim Warwick
MA (Cantab), 46
COO

Jim Warwick has an MA in Computer Science from the University of Cambridge. From 1986 to 2003 he worked for Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim joined Abcam in 2001 as Technical Director, focusing on the development of the website and the systems integral to support it, and took over operational management of the UK office as Managing Director in June 2004. In this capacity he worked on both cost-saving and efficiency improvement projects, including the bar-coding and automation of inventory handling within the Group. Jim is responsible for overseeing the operational strategy of the business and in particular ensuring the continued scalability and efficiency of the Company. In 2009, Jim took on the role of Chief Operating Officer, with operational responsibility for the Group as a whole.

Peter Keen
BSc (Econ), ACA, 54
Non-executive and Senior Independent Director

Peter Keen joined Abcam’s Board in October 2005 prior to the Company’s IPO and is a chartered accountant with more than 25 years experience in the financing and management of biotechnology companies. He is chairman of Oval Medical Technologies Ltd and Exosect Limited and a non-executive director of Ark Therapeutics Group plc and the Biotech Growth Trust plc. Peter has a notable track record in the UK biotechnology sector and until March 2010 was corporate development and finance director of the private biotechnology company Serentis Ltd. He was co-founder and finance director of Chiroscience Group plc after which he helped establish Merlin Biosciences Limited, where he was responsible for a number of investments including Ark Therapeutics Group plc, Cyclacel, ReNeuron plc and Vectura Group plc. More recently, he was chief financial officer of Arakis Limited until its successful trade sale in 2005, and a partner with the technology venture firm DFJ Esprit LLP.

Murray Hennessy,
MA (Econ), 50
Non-executive Director

Murray Hennessy has an impressive track record of working internationally in customer-facing industries. He is currently chief executive of thetrainline.com, the online train ticket retailer, which he joined in 2008, prior to which he was chief executive of Avis Europe plc, the car rental company. Between 2001 and 2004, Murray was the commercial director of John Lewis Department Stores where he pioneered the store's online presence, johnlewis.com. After an early career as a management consultant in the London, Tokyo and Boston offices of Bain & Company, Murray held a number of senior positions in the restaurants industry and also led an internet start-up.

Anthony Kouzarides, PhD, 54
Non-executive Director

Tony Kouzarides is a co-founder of Abcam and has played a key role in expanding Abcam’s antibody product range into the chromatin research area. Professor Kouzarides holds the Royal Society Napier Professorship in Cancer Biology at the University of Cambridge, UK, where he leads a laboratory that investigates the basic cellular role of chromatin-modifying enzymes and their role in human cancer. He is a co-founder of Chroma Therapeutics Limited, which identifies drugs against cancer, and is the founder and director of cancer charity Vencer el Cancer, operating in Spain.

Anthony Martin, PhD, 57
Non-executive Director

Tony Martin has over 20 years' experience in providing life science, medical device and diagnostic companies counsel on a range of strategic, management and funding matters. He joined Abcam's Board as a Non-Executive Director in September 2011. Tony is the Founder and Managing Partner of TMA Consultants, which provides business planning and interim management for high tech medical companies. He has most recently served as Chairman of Molecular Insight Pharmaceuticals Inc., a NASDAQ quoted biopharm company specialising in new radiotherapies for heart disease and cancer. He was also Non-Executive Director of Prelude Trust plc, an investment trust that specialised in early-stage, technology-based businesses; and as Chairman of NeuTec Pharma plc, he played a pivotal role in guiding the company's listing on the AIM market and its subsequent sale to Novartis. He has also held senior positions in a number of well-known life science businesses both in the UK and US including: Managing Director of British Biotech Products Ltd, Chairman, President and CEO of Molecular Probes, President of Molecular Biology, Invitrogen Corporation, Chairman and CEO of AZUR Environmental, CEO of Celsis International plc, as well as senior leadership roles at Amersham International plc. Tony holds a Ph.D. in Immunology and a first class honors degree in Applied Chemistry from the Universities of Manchester and Huddersfield, UK. He is currently Chairman of Immunodiagnostic Systems Holdings plc, Sphere Medical Holding plc, Wound Solutions Ltd, Phico Therapeutics Ltd and 1Voice1Vision Ltd.

Michael Ross,
MA (Cantab), 42
Non-executive Director

Michael Ross is an e-commerce executive and adviser with a high level of technical expertise. He co-founded eCommera in 2006, an e-commerce technology and advisory business where he is an executive director. He is currently a non-executive director of warehouseexpress.com and of Prescription Eyewear Limited, which operates the glassesdirect.com website. He is also an e-commerce adviser to a number of other businesses. After working in management consultancy at McKinsey & Company, Michael co-founded the online retailer figleaves.com in 1999, where he was chief executive officer until 2006.